Clinical trial · Interventional
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors
NCT03351231CI-TRIAL-00046822terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Inability to meet protocol objectives
Summary
Brief summary (as posted)
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986242 | Drug | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Dose Escalation
- description
- BMS-986242 administered in combination with Nivolumab
- interventionNames
- Drug: BMS-986242
- Biological: Nivolumab
- type
- EXPERIMENTAL
- label
- Dose Expansion
- description
- BMS-986242 administered in combination with Nivolumab
- interventionNames
- Drug: BMS-986242
- Biological: Nivolumab
Primary outcomes (6)
- measure
- Number of Participants With Adverse Events (AE)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1 * Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Ability to swallow tablets * Adequate bone marrow and organ function, as defined by the protocol Exclusion Criteria: * Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll) * Ocular melanoma * Any significant acute or chronic medical illness * Prior malignancy * Other active malignancy requiring concurrent intervention * Prior organ allograft or allogeneic bone marrow transplantation * Participants with active, known, or suspected autoimmune disease * Requirement for daily supplemental oxygen * Uncontrolled or significant cardiovascular disease * Pre-existing liver disease * Gastrointestinal disease known to interfere with absorption Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.